Decolonization of Gram-negative Multi-resistant Organisms (MDRO) With Donor Microbiota (FMT)

Resistance Bacterial Clinical Trial

— DEKODON  

Official title:

DEKODON: Decolonization of Gram-negative Multi-resistant Organisms (MDRO) With Donor Microbiota (FMT)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04188743
• Other study ID #: BC-3034
• Secondary ID: 2018/0966
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: December 18, 2019
• Est. completion date: December 30, 2025

Study information

• Verified date: December 2023
• Source: University Hospital, Ghent
• Contact: Bruno Verhasselt, Prof. Dr.
• Phone: +3293322226
• Email: bruno.verhasselt[@]uzgent.be
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Colonization by Multiple Drug Resistant Organisms (MDROs) during patient hospitalization requires expensive isolation measures and renders the return or transfer to other departments or institutions often impossible. Currently there is no specific treatment available. Patients have to wait for spontaneous clearance which can take months or does not happen at all.

The study will test the effect of Fecal Microbiota Transfer (FMT) on gut MDRO colonization. The focus will be on patients with a long-term colonization by Gram-negative bacteria for which isolation is warranted. Participants will be randomized into two treatment groups; allogenic FMT versus autologous FMT. A third group of participants will be monitored but will not receive an FMT. Decolonization rate will be compared one month after treatment. Additionally gut microbial composition will be studied up to one year after FMT.

Description:

This double-blind controlled randomized study will test the efficacy of Fecal Microbiota Transfer (FMT) on gut Multiple Drug Resistant Organism (MDRO) colonization.

Participants:

The study targets hospitalized patients (>18 years old) that need to stay in isolation because of colonization by Carbapenem-resistant Enterobacteriales (CRE), non-E. coli Enterobacteriales that produce extended spectrum beta-lactamase (ESBL) or Multi Drug Resistant (MDR) Pseudomonas and MDR Acinetobacter species. Participants will be randomized in two groups (allogenic and autologous FMT). Additionally a third group of participants will be monitored without intervention.

Treatment:

Participants in the allogenic FMT- group will receive treatment using healthy donor microbiota preferably through naso-duodenal/-jejunal administration (Cortrak). Donor material will be supplied by the Ghent Stool Bank. The colonization status will be monitored on a regular basis (at least once per week) by culturing fecal swabs. Additionally fecal samples will be taken on fixed time points for microbial composition analysis (16S ribosomal ribonucleic acid metagenomics).

Controls:

Participants in the autologous FMT-group will will receive an FMT with their own microbiota to account for the effects of the intervention itself. Participants in the "no intervention" group will not receive an FMT. Both control groups will be monitored and sampled identically to the allogenic FMT-group.

Outcome:

The primary outcome (MDRO-decolonization rate in treatment versus control) will be evaluated 1 month after FMT. Secondarily, safety and tolerability of the treatment will be assessed. The patients will be monitored up to 1 year after treatment to evaluate microbiome composition and to define parameters in the microbiome that are associated with clinical outcome.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: December 30, 2025
• Est. primary completion date: December 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants must be at least 18 years of age, and must sign the 'informed consent' form and thus agree with the data collection, sampling and FMT.

• At least 2 consecutive confirmations of MDRO colonization in faeces, which complicate the necessary follow-up and/or therapy for the patient.

• Participants must be able to endure the treatment (evaluated by treating physician).

Exclusion Criteria:

• Inflammatory bowel disease (Crohn's disease, ulcerative colitis ...)

• Diagnosed hereditary blood disease (Haemophilia, Von Willebrand ...)

• Chronic liver disease

• Active drug use or alcohol abuse / dependence, which according to the researchers' opinion may interfere with the patient's participation in the study

• Simultaneous use of probiotics (except yoghurt)

• Existing immune deficiency (congenital or acquired), or concomitant immunomodulatory treatment (including systemic corticosteroids) in the 12 weeks prior to randomization, nasal or inhaled corticosteroid use is permitted

• Positive pregnancy test (or potentially pregnant)

• Breastfeeding

• Severe food allergy (anaphylaxis, urticarial)

• Antibiotic treatment up to 7 days before FMT, or planned to start within one month after FMT.

Related Conditions & MeSH terms

• Resistance Bacterial

Intervention

Biological:
• Allogenic FMT
Transplantation of fecal microbiota from a donor into a recipient
• Autologous FMT
Transplantation of autologous fecal microbiota

Locations

Country	Name	City	State
Belgium	Ghent University Hospital	Ghent	Oost-Vlaanderen

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Ghent	Research Foundation Flanders

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with decolonization success/failure	These participants were screened positive for MDRO's in stool cultures before treatment and monitored at least once per week up to 1 month after treatment. "Decolonization" = 3 consecutive negative cultures in minimal time span of 2 weeks.	1 month after treatment
Secondary	Side effects	Monitor adverse events	up to 1 year after treatment
Secondary	Treatment effect on microbial community in participants	Evaluation of gut bacterial composition changes in participants over time pre- and post-treatment with 16S ribosomal ribonucleic acid based metagenomic analysis.	up to 1 year after treatment
Secondary	Treatment tolerability	The tolerability of the treatment is monitored with an in-house developed questionnaire considering the participant's opinion before, during and after the treatment on a score of 1 (very bad) to 5 (very good).	1 month after treatment